Evidence map›Paper›PMID 42045536›Full record

ArticleOncogene2026

METTL1-mediated m

Huiwu Xing, Fuqiang Ma, Penghui Li, Mengjuan Xuan, Yingru Liu, Leiya Fu, Na Lou, Yafeng Liu, Shujun Zhang, Ziyi Xu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Huiwu Xing *Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fuqiang Ma *Department of Integrated Traditional and Western Medicine, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China.
Penghui Li *Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
Mengjuan XuanDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yingru LiuDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Leiya FuDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Na LouDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yafeng LiuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
Shujun ZhangHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
Ziyi XuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
Yuting HeDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. fccheyt1@zzu.edu.cn.ORCID http://orcid.org/0000-0003-1704-3771
Chen XueDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. xchenzzu@163.com.
Xinyu GuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China. stargu6932@163.com.ORCID http://orcid.org/0009-0006-7019-5749

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a prevalent and aggressive malignancy, notorious for its high recurrence, substantial drug resistance, and poor prognosis. Although METTL1, a key regulator of RNA m

Indexed as

AsparagineAspartate-Ammonia LigaseCarcinoma, HepatocellularLiver NeoplasmsMethyltransferasesRNA, MessengerAnimalsCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpitranscriptomeGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingASNS protein, humanAsparagineAspartate-Ammonia LigaseCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorMethyltransferasesMETTL1 protein, humanRNA, MessengerTOR Serine-Threonine Kinases

Identifiers

PMID42045536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.